Cargando…
Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia
The aim of this study was to assess the clinical effectiveness of Hydroxychloroquine-based regimens versus standard treatment in patients with the coronavirus disease admitted in 2019 to a hospital in Saudi Arabia. A comparative observational study, using routine hospital data, was carried out in a...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065820/ https://www.ncbi.nlm.nih.gov/pubmed/33807320 http://dx.doi.org/10.3390/antibiotics10040365 |
_version_ | 1783682430158241792 |
---|---|
author | Alghamdi, Saleh Barakat, Bassant Berrou, Ilhem Alzahrani, Abdulhakim Haseeb, Abdul Hammad, Mohamed Anwar Anwar, Sirajudheen Sindi, Abdulmajeed Abdulghani A. Almasmoum, Hussain A. Albanghali, Mohammad |
author_facet | Alghamdi, Saleh Barakat, Bassant Berrou, Ilhem Alzahrani, Abdulhakim Haseeb, Abdul Hammad, Mohamed Anwar Anwar, Sirajudheen Sindi, Abdulmajeed Abdulghani A. Almasmoum, Hussain A. Albanghali, Mohammad |
author_sort | Alghamdi, Saleh |
collection | PubMed |
description | The aim of this study was to assess the clinical effectiveness of Hydroxychloroquine-based regimens versus standard treatment in patients with the coronavirus disease admitted in 2019 to a hospital in Saudi Arabia. A comparative observational study, using routine hospital data, was carried out in a large tertiary care hospital in Al Baha, Saudi Arabia, providing care to patients with COVID-19 between April 2019 and August 2019. Patients were categorized into two groups: the Hydroxychloroquine (HCQ) group, treated with HCQ in a dose of 400 mg twice daily on the first day, followed by 200 mg twice daily; the non HCQ group, treated with other antiviral or antibacterial treatments according to protocols recommended by the Ministry of Health (MOH) at the time. The primary outcomes were the length of hospital stay, need for admission to the intensive care unit (ICU), time in ICU, and need for mechanical ventilation. Overall survival was also assessed. 568 patients who received HCQ (treatment group) were compared with 207 patients who did not receive HCQ (control group). HCQ did not improve mortality in the treated group (7.7% vs. 7.2%). There were no significant differences in terms of duration of hospitalization, need for and time in ICU, and need for mechanical ventilation among the groups. Our study provides further evidence that HCQ treatment does not reduce mortality rates, length of hospital stay, admission and time in ICU, and need for mechanical ventilation in patients hospitalized with COVID-19. |
format | Online Article Text |
id | pubmed-8065820 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80658202021-04-25 Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia Alghamdi, Saleh Barakat, Bassant Berrou, Ilhem Alzahrani, Abdulhakim Haseeb, Abdul Hammad, Mohamed Anwar Anwar, Sirajudheen Sindi, Abdulmajeed Abdulghani A. Almasmoum, Hussain A. Albanghali, Mohammad Antibiotics (Basel) Article The aim of this study was to assess the clinical effectiveness of Hydroxychloroquine-based regimens versus standard treatment in patients with the coronavirus disease admitted in 2019 to a hospital in Saudi Arabia. A comparative observational study, using routine hospital data, was carried out in a large tertiary care hospital in Al Baha, Saudi Arabia, providing care to patients with COVID-19 between April 2019 and August 2019. Patients were categorized into two groups: the Hydroxychloroquine (HCQ) group, treated with HCQ in a dose of 400 mg twice daily on the first day, followed by 200 mg twice daily; the non HCQ group, treated with other antiviral or antibacterial treatments according to protocols recommended by the Ministry of Health (MOH) at the time. The primary outcomes were the length of hospital stay, need for admission to the intensive care unit (ICU), time in ICU, and need for mechanical ventilation. Overall survival was also assessed. 568 patients who received HCQ (treatment group) were compared with 207 patients who did not receive HCQ (control group). HCQ did not improve mortality in the treated group (7.7% vs. 7.2%). There were no significant differences in terms of duration of hospitalization, need for and time in ICU, and need for mechanical ventilation among the groups. Our study provides further evidence that HCQ treatment does not reduce mortality rates, length of hospital stay, admission and time in ICU, and need for mechanical ventilation in patients hospitalized with COVID-19. MDPI 2021-03-31 /pmc/articles/PMC8065820/ /pubmed/33807320 http://dx.doi.org/10.3390/antibiotics10040365 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Alghamdi, Saleh Barakat, Bassant Berrou, Ilhem Alzahrani, Abdulhakim Haseeb, Abdul Hammad, Mohamed Anwar Anwar, Sirajudheen Sindi, Abdulmajeed Abdulghani A. Almasmoum, Hussain A. Albanghali, Mohammad Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia |
title | Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia |
title_full | Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia |
title_fullStr | Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia |
title_full_unstemmed | Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia |
title_short | Clinical Efficacy of Hydroxychloroquine in Patients with COVID-19: Findings from an Observational Comparative Study in Saudi Arabia |
title_sort | clinical efficacy of hydroxychloroquine in patients with covid-19: findings from an observational comparative study in saudi arabia |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8065820/ https://www.ncbi.nlm.nih.gov/pubmed/33807320 http://dx.doi.org/10.3390/antibiotics10040365 |
work_keys_str_mv | AT alghamdisaleh clinicalefficacyofhydroxychloroquineinpatientswithcovid19findingsfromanobservationalcomparativestudyinsaudiarabia AT barakatbassant clinicalefficacyofhydroxychloroquineinpatientswithcovid19findingsfromanobservationalcomparativestudyinsaudiarabia AT berrouilhem clinicalefficacyofhydroxychloroquineinpatientswithcovid19findingsfromanobservationalcomparativestudyinsaudiarabia AT alzahraniabdulhakim clinicalefficacyofhydroxychloroquineinpatientswithcovid19findingsfromanobservationalcomparativestudyinsaudiarabia AT haseebabdul clinicalefficacyofhydroxychloroquineinpatientswithcovid19findingsfromanobservationalcomparativestudyinsaudiarabia AT hammadmohamedanwar clinicalefficacyofhydroxychloroquineinpatientswithcovid19findingsfromanobservationalcomparativestudyinsaudiarabia AT anwarsirajudheen clinicalefficacyofhydroxychloroquineinpatientswithcovid19findingsfromanobservationalcomparativestudyinsaudiarabia AT sindiabdulmajeedabdulghania clinicalefficacyofhydroxychloroquineinpatientswithcovid19findingsfromanobservationalcomparativestudyinsaudiarabia AT almasmoumhussaina clinicalefficacyofhydroxychloroquineinpatientswithcovid19findingsfromanobservationalcomparativestudyinsaudiarabia AT albanghalimohammad clinicalefficacyofhydroxychloroquineinpatientswithcovid19findingsfromanobservationalcomparativestudyinsaudiarabia |